{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:07:45Z","timestamp":1791230865976,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09883-1","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:53:05Z","timestamp":1783565585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Secondary Prophylaxis of Recurrent Clostridioides difficile Infections During Systemic Antibiotics with Vancomycin (SPORES-V): study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6790-220X","authenticated-orcid":false,"given":"Connor","family":"Prosty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Carignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Daneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Kandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Longtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Perez-Patrigeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Wuerz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cheaveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susy S.","family":"Hota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olusola","family":"Ogundipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore S.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L. Y.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Archambault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bergevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Girouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leighanne","family":"Parkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Reinblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"MacFadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"14","key":"9883_CR1","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","volume":"382","author":"AY Guh","year":"2020","unstructured":"Guh AY, Mu Y, Winston LG, et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382(14):1320\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1910215.","journal-title":"N Engl J Med"},{"issue":"3","key":"9883_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv076","volume":"2","author":"AR Levy","year":"2015","unstructured":"Levy AR, Szabo SM, Lozano-Ortega G, et al. Incidence and costs of Clostridium difficile infections in Canada. Open Forum Infect Dis. 2015;2(3):ofv076. https:\/\/doi.org\/10.1093\/ofid\/ofv076.","journal-title":"Open Forum Infect Dis"},{"key":"9883_CR3","doi-asserted-by":"publisher","unstructured":"Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55 Suppl 2(Suppl 2):S88\u201392. https:\/\/doi.org\/10.1093\/cid\/cis335.","DOI":"10.1093\/cid\/cis335"},{"issue":"Suppl 2","key":"9883_CR4","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1093\/cid\/cis356","volume":"55","author":"DW Eyre","year":"2012","unstructured":"Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;55(Suppl 2):S77\u201387. https:\/\/doi.org\/10.1093\/cid\/cis356.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"5","key":"9883_CR5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/jamainternmed.2015.42","volume":"175","author":"EG McDonald","year":"2015","unstructured":"McDonald EG, Milligan J, Frenette C, Lee TC. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med. 2015;175(5):784\u201391. https:\/\/doi.org\/10.1001\/jamainternmed.2015.42.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"9883_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cmi.2014.08.017","volume":"21","author":"MA Olsen","year":"2015","unstructured":"Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect. 2015;21(2):164\u201370. https:\/\/doi.org\/10.1016\/j.cmi.2014.08.017.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"9883_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhin.2020.09.025","volume":"106","author":"DA Enoch","year":"2020","unstructured":"Enoch DA, Murray-Thomas T, Adomakoh N, et al. Risk of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection: a retrospective observational database study in England. J Hosp Infect. 2020;106(4):793\u2013803. https:\/\/doi.org\/10.1016\/j.jhin.2020.09.025.","journal-title":"J Hosp Infect"},{"issue":"2","key":"9883_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmicom.2025.105079","volume":"2","author":"LC Louren\u00e7o","year":"2025","unstructured":"Louren\u00e7o LC, Prosty C, Huttner A, Lee TC, McDonald EG. Approach to Clostridioides difficile diarrheal infection. CMI Commun. 2025;2(2):105079. https:\/\/doi.org\/10.1016\/j.cmicom.2025.105079.","journal-title":"CMI Commun"},{"issue":"1","key":"9883_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmi.2023.09.002","volume":"30","author":"Y Stabholz","year":"2024","unstructured":"Stabholz Y, Paul M. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis. Clin Microbiol Infect. 2024;30(1):51\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2023.09.002.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"9883_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"TJ Louie","year":"2011","unstructured":"Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus Vancomycin for Clostridium difficile Infection. N Engl J Med. 2011;364(5):422\u201331. https:\/\/doi.org\/10.1056\/NEJMoa0910812.","journal-title":"N Engl J Med"},{"key":"9883_CR11","doi-asserted-by":"publisher","unstructured":"Patel D, Senecal J, Spellberg B, et al. Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada? JAC Antimicrob Resist. 2023;5(1):dlac138. https:\/\/doi.org\/10.1093\/jacamr\/dlac138.","DOI":"10.1093\/jacamr\/dlac138"},{"issue":"4","key":"9883_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa1602615","volume":"376","author":"MH Wilcox","year":"2017","unstructured":"Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1602615.","journal-title":"N Engl J Med"},{"issue":"5","key":"9883_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1056\/NEJMoa1205037","volume":"368","author":"E Van Nood","year":"2013","unstructured":"Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J Med. 2013;368(5):407\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1205037.","journal-title":"N Engl J Med"},{"issue":"9","key":"9883_CR14","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/cid\/ciac207","volume":"75","author":"ES Aby","year":"2022","unstructured":"Aby ES, Vaughn BP, Enns EA, Rajasingham R. Cost-effectiveness of fecal microbiota transplantation for first recurrent Clostridioides difficile infection. Clin Infect Dis. 2022;75(9):1602\u20139. https:\/\/doi.org\/10.1093\/cid\/ciac207.","journal-title":"Clin Infect Dis"},{"issue":"21","key":"9883_CR15","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","volume":"381","author":"Z DeFilipp","year":"2019","unstructured":"DeFilipp Z, Bloom PP, Soto MT, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381(21):2043\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1910437.","journal-title":"N Engl J Med"},{"key":"9883_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","volume":"27","author":"J van Prehn","year":"2021","unstructured":"van Prehn J, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27:S1\u201321. https:\/\/doi.org\/10.1016\/j.cmi.2021.09.038.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"9883_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa2106516","volume":"386","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386(3):220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2106516.","journal-title":"N Engl J Med"},{"issue":"15","key":"9883_CR18","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","volume":"82","author":"S Khanna","year":"2022","unstructured":"Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527\u201338. https:\/\/doi.org\/10.1007\/s40265-022-01797-x.","journal-title":"Drugs"},{"issue":"1","key":"9883_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1086\/649016","volume":"31","author":"AK Sethi","year":"2010","unstructured":"Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol. 2010;31(1):21\u20137. https:\/\/doi.org\/10.1086\/649016.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"10","key":"9883_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076269","volume":"8","author":"T Abujamel","year":"2013","unstructured":"Abujamel T, Cadnum JL, Jury LA, et al. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS ONE. 2013;8(10):e76269. https:\/\/doi.org\/10.1371\/journal.pone.0076269.","journal-title":"PLoS ONE"},{"issue":"8","key":"9883_CR21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jiac.2019.03.011","volume":"25","author":"T Kimura","year":"2019","unstructured":"Kimura T, Snijder R, Sugitani T. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: a nationwide real-world analysis using a large hospital-based administrative dataset. J Infect Chemother Off J Jpn Soc Chemother. 2019;25(8):615\u201320. https:\/\/doi.org\/10.1016\/j.jiac.2019.03.011.","journal-title":"J Infect Chemother Off J Jpn Soc Chemother"},{"issue":"4","key":"9883_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.7326\/0003-4819-117-4-297","volume":"117","author":"S Johnson","year":"1992","unstructured":"Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (Fecal Excretors) with vancomycin or metronidazole. Ann Intern Med. 1992;117(4):297\u2013302. https:\/\/doi.org\/10.7326\/0003-4819-117-4-297.","journal-title":"Ann Intern Med"},{"issue":"12","key":"9883_CR23","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/ajg.2016.417","volume":"111","author":"A Carignan","year":"2016","unstructured":"Carignan A, Poulin S, Martin P, et al. Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections. Am J Gastroenterol. 2016;111(12):1834. https:\/\/doi.org\/10.1038\/ajg.2016.417.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"9883_CR24","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1017\/ice.2019.88","volume":"40","author":"DA Caroff","year":"2019","unstructured":"Caroff DA, Menchaca JT, Zhang Z, et al. Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridiodes difficile infection relapses. Infect Control Hosp Epidemiol. 2019;40(6):662\u20137. https:\/\/doi.org\/10.1017\/ice.2019.88.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"9883_CR25","doi-asserted-by":"publisher","unstructured":"Prosty C, Bortolussi-Courval \u00c9, Dub\u00e9 LR, Lee TC, McDonald EG. Oral vancomycin prophylaxis for the prevention of recurrent Clostridioides difficile infection during re-exposure to systemic antibiotics: a systematic review and meta-analysis. CMI Commun. 2024;1(2). https:\/\/doi.org\/10.1016\/j.cmicom.2024.105041.","DOI":"10.1016\/j.cmicom.2024.105041"},{"issue":"5","key":"9883_CR26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/cid\/ciz966","volume":"71","author":"SW Johnson","year":"2020","unstructured":"Johnson SW, Brown SV, Priest DH. Effectiveness of oral vancomycin for prevention of healthcare facility-onset Clostridioides difficile infection in targeted patients during systemic antibiotic exposure. Clin Infect Dis. 2020;71(5):1133\u20139. https:\/\/doi.org\/10.1093\/cid\/ciz966.","journal-title":"Clin Infect Dis"},{"key":"9883_CR27","doi-asserted-by":"publisher","unstructured":"Keating JA, Xu T, Graham MB, et al. Oral vancomycin for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA Netw Open. 2025;8(7):e2517834. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.17834.","DOI":"10.1001\/jamanetworkopen.2025.17834"},{"issue":"2","key":"9883_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlag032","volume":"8","author":"R San-Juan","year":"2026","unstructured":"San-Juan R, Orig\u00fcen J, Fern\u00e1ndez-Ruiz M, et al. Randomized double-blind clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin versus placebo in the prevention of recurrence of Clostridioides difficile infection in patients receiving systemic antibiotic therapy (PREVAN trial). JAC-Antimicrob Resist. 2026;8(2):dlag032. https:\/\/doi.org\/10.1093\/jacamr\/dlag032.","journal-title":"JAC-Antimicrob Resist"},{"issue":"6","key":"9883_CR29","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","volume":"116","author":"CR Kelly","year":"2021","unstructured":"Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021;116(6):1124. https:\/\/doi.org\/10.14309\/ajg.0000000000001278.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"9883_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3138\/jammi.2018.02.13","volume":"3","author":"VG Loo","year":"2018","unstructured":"Loo VG, Davis I, Embil J, et al. Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection. Off J Assoc Med Microbiol Infect Dis Can. 2018;3(2):71\u201392. https:\/\/doi.org\/10.3138\/jammi.2018.02.13.","journal-title":"Off J Assoc Med Microbiol Infect Dis Can"},{"issue":"5","key":"9883_CR31","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","volume":"73","author":"S Johnson","year":"2021","unstructured":"Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029\u201344. https:\/\/doi.org\/10.1093\/cid\/ciab549.","journal-title":"Clin Infect Dis"},{"key":"9883_CR32","doi-asserted-by":"publisher","unstructured":"Prosty C, Bortolussi-Courval \u00c9, Lee J, Lee TC, McDonald EG. Global practice variation in the management of Clostridioides difficile infections: an international cross-sectional survey of clinicians. Open Forum Infect Dis. Published online April 24, 2025:ofaf248. https:\/\/doi.org\/10.1093\/ofid\/ofaf248.","DOI":"10.1093\/ofid\/ofaf248"},{"key":"9883_CR33","doi-asserted-by":"publisher","unstructured":"Herrera-Perez D, Haslam A, Crain T, et al. A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. Franco E, Elshaug A, eds. eLife. 2019;8:e45183. https:\/\/doi.org\/10.7554\/eLife.45183.","DOI":"10.7554\/eLife.45183"},{"issue":"8","key":"9883_CR34","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.mayocp.2013.05.012","volume":"88","author":"V Prasad","year":"2013","unstructured":"Prasad V, Vandross A, Toomey C, et al. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc. 2013;88(8):790\u20138. https:\/\/doi.org\/10.1016\/j.mayocp.2013.05.012.","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"9883_CR35","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/s41562-021-01177-7","volume":"5","author":"JK Kruschke","year":"2021","unstructured":"Kruschke JK. Bayesian analysis reporting guidelines. Nat Hum Behav. 2021;5(10):1282\u201391. https:\/\/doi.org\/10.1038\/s41562-021-01177-7.","journal-title":"Nat Hum Behav"},{"issue":"23","key":"9883_CR36","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/jama.2022.21243","volume":"328","author":"NJ Butcher","year":"2022","unstructured":"Butcher NJ, Monsour A, Mew EJ, et al. Guidelines for reporting outcomes in trial protocols: the SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345\u201356. https:\/\/doi.org\/10.1001\/jama.2022.21243.","journal-title":"JAMA"},{"issue":"20","key":"9883_CR37","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.","journal-title":"JAMA"},{"key":"9883_CR38","doi-asserted-by":"publisher","unstructured":"Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. Jama. 2015;313(17):1719\u20131727. https:\/\/doi.org\/10.1001\/jama.2015.3725.","DOI":"10.1001\/jama.2015.3725"},{"key":"9883_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208.","journal-title":"J Biomed Inform"},{"key":"9883_CR40","unstructured":"Create a blocked randomisation list | Sealed Envelope. https:\/\/www.sealedenvelope.com\/simple-randomiser\/v1\/lists. Accessed 26 Feb 2026."},{"issue":"5","key":"9883_CR41","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/cid\/ciw401","volume":"63","author":"NW Van Hise","year":"2016","unstructured":"Van Hise NW, Bryant AM, Hennessey EK, Crannage AJ, Khoury JA, Manian FA. Efficacy of oral vancomycin in preventing recurrent Clostridium difficile infection in patients treated with systemic antimicrobial agents. Clin Infect Dis. 2016;63(5):651\u20133. https:\/\/doi.org\/10.1093\/cid\/ciw401.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"9883_CR42","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.bbmt.2019.06.021","volume":"25","author":"T Morrisette","year":"2019","unstructured":"Morrisette T, Van Matre AG, Miller MA, et al. Oral vancomycin prophylaxis as secondary prevention against Clostridioides difficile infection in the hematopoietic stem cell transplantation and hematologic malignancy population. Biol Blood Marrow Transplant. 2019;25(10):2091\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2019.06.021.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"9883_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1060028017727756","volume":"52","author":"LE Splinter","year":"2018","unstructured":"Splinter LE, Kerstenetzky L, Jorgenson MR, et al. Vancomycin prophylaxis for prevention of Clostridium difficile infection recurrence in renal transplant patients. Ann Pharmacother. 2018;52(2):113\u20139. https:\/\/doi.org\/10.1177\/1060028017727756.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"9883_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.60495","volume":"9","author":"EG McDonald","year":"2026","unstructured":"McDonald EG, Butler-Laporte G, Brophy JM, et al. Initial vancomycin taper for the prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA Netw Open. 2026;9(2):e2560495. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.60495.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"9883_CR45","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/cid\/ciad523","volume":"78","author":"C Prosty","year":"2024","unstructured":"Prosty C, Hanula R, Katergi K, Longtin Y, McDonald EG, Lee TC. Clinical outcomes and management of NAAT-positive\/toxin-negative Clostridioides difficile infection: a systematic review and meta-analysis. Clin Infect Dis. 2024;78(2):430\u20138. https:\/\/doi.org\/10.1093\/cid\/ciad523.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"9883_CR46","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jac\/dkr508","volume":"67","author":"MPM Hensgens","year":"2012","unstructured":"Hensgens MPM, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742\u20138. https:\/\/doi.org\/10.1093\/jac\/dkr508.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"9883_CR47","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cix1085","volume":"66","author":"LC McDonald","year":"2018","unstructured":"McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1\u201348. https:\/\/doi.org\/10.1093\/cid\/cix1085.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"9883_CR48","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2011;20(10):1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"key":"9883_CR49","unstructured":"CTCAE and AE Reporting - NCI. 2025. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events. Accessed 20 Sept 2025."},{"issue":"2","key":"9883_CR50","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1214\/aos\/1176325489","volume":"22","author":"S Bose","year":"1994","unstructured":"Bose S. Bayesian robustness with mixture classes of priors. Ann Stat. 1994;22(2):652\u201367.","journal-title":"Ann Stat"},{"issue":"3","key":"9883_CR51","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1198\/004017007000000245","volume":"49","author":"A Genkin","year":"2007","unstructured":"Genkin A, Lewis DD, Madigan D. Large-scale bayesian logistic regression for text categorization. Technometrics. 2007;49(3):291\u2013304. https:\/\/doi.org\/10.1198\/004017007000000245.","journal-title":"Technometrics"},{"key":"9883_CR52","unstructured":"[2011.01808] Bayesian workflow. https:\/\/arxiv.org\/abs\/2011.01808. Accessed 4 Oct 2025."},{"issue":"14","key":"9883_CR53","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","volume":"367","author":"RJ Little","year":"2012","unstructured":"Little RJ, D\u2019Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355\u201360. https:\/\/doi.org\/10.1056\/NEJMsr1203730.","journal-title":"N Engl J Med"},{"key":"9883_CR54","doi-asserted-by":"publisher","first-page":"b2393","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JAC Sterne","year":"2009","unstructured":"Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393. https:\/\/doi.org\/10.1136\/bmj.b2393.","journal-title":"BMJ"},{"key":"9883_CR55","unstructured":"Bunny Wipe Fecal Sample Collector. Zymo Research International. https:\/\/zymoresearch.eu\/products\/bunny-wipe-fecal-sample-collector . Accessed 4 Oct 2025."},{"issue":"1","key":"9883_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-54037-5","volume":"14","author":"K Giersch","year":"2024","unstructured":"Giersch K, Tanida K, Both A, et al. Adaptation and validation of a quantitative vanA\/vanB DNA screening assay on a high-throughput PCR system. Sci Rep. 2024;14(1):3523. https:\/\/doi.org\/10.1038\/s41598-024-54037-5.","journal-title":"Sci Rep"},{"issue":"6","key":"9883_CR57","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1001\/jamainternmed.2016.0177","volume":"176","author":"Y Longtin","year":"2016","unstructured":"Longtin Y, Paquet-Bolduc B, Gilca R, et al. Effect of detecting and isolating Clostridium difficile carriers at hospital admission on the incidence of C difficile infections: a quasi-experimental controlled study. JAMA Intern Med. 2016;176(6):796\u2013804. https:\/\/doi.org\/10.1001\/jamainternmed.2016.0177.","journal-title":"JAMA Intern Med"},{"issue":"8","key":"9883_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad413","volume":"10","author":"AC Miller","year":"2023","unstructured":"Miller AC, Arakkal AT, Sewell DK, et al. Comparison of different antibiotics and the risk for community-associated Clostridioides difficile infection: a case\u2013control study. Open Forum Infect Dis. 2023;10(8):ofad413. https:\/\/doi.org\/10.1093\/ofid\/ofad413.","journal-title":"Open Forum Infect Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09883-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09883-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09883-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:02:10Z","timestamp":1790895730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09883-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9883"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09883-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MUHC REB 2025\u201311089. Written informed consent to participate will be obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Model consent forms will be provided upon request.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"590"}}